ArticleGynecologic oncology reports2026
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Platinum-based chemotherapy remains the cornerstone of treatment for recurrent ovarian cancer; however, optimal treatment sequencing after progression on PARP inhibitors (PARPi) remains uncertain, particularly in patients with partially platinum-sensitive disease. Objective: to evaluate the efficacy, safety, and subsequent treatment patterns associated with trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer who had progressed after prior PARPi exposure. Methods: This retrospective, single-center real-world study included patients with recurrent ovarian cancer, a platinum-free interval of 6-12 months, and progression after prior PARPi exposure. Results: Twenty-five patients were included. The median age was 68.8 years, median platinum-free interval was 7.0 months, and patients had received a median of three prior lines of therapy. The objective response rate (ORR) was 24.0% and disease control rate (DCR) was 64.0%. Median progression-free survival (PFS) and overall survival (OS) were 7.9 and 19.9 months, respectively. Following progression on trabectedin plus PLD, 76.0% of patients received subsequent platinum-based chemotherapy, with an ORR of 33.3% among those receiving immediate platinum rechallenge. Toxicities were predominantly hematological, with no unexpected safety signals. Conclusions: In this real-world, heavily pretreated post-PARPi population with partially platinum-sensitive disease, trabectedin plus PLD demonstrated clinically meaningful activity with an acceptable safety profile. In a setting where available evidence remains limited and heterogeneous, these findings provide additional clinically relevant data in a well-defined subgroup and support its use as a feasible treatment option in selected patients. Prospective studies are warranted to further define optimal treatment sequencing after PARPi exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.